Thomas Kerry McCarter is listed as an executive officer on 4 SEC Form D filings by 2 issuers between Sep 2018 and Feb 2022: ReAlta Life Sciences, Inc. (Norfolk, VA — biotechnology — 2018–2020; $29.9M reported sold to 149 investors) and INTERLEUKIN COMBINATORIAL THERAPIES, INC. (Henrico, VA — other health care — 2022; $2.6M reported sold to 6 investors).
What this means 2 separate companies raised money with this person listed as executive officer, over about 4 years. Across those companies the filings report $32.5M sold in total.
Listed alongside Edward Heidt, Jr. (3 shared filings), Kenji Cunnion (3 shared filings), Neel Krishna (3 shared filings), Ulrich Thienel (3 shared filings), Barry Strasnick (2 shared filings) and 11 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Thomas. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 1 court case matching the name, 8 bankruptcy cases matching the name listed in Key records below.
What this means 9 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 4 public filings for Thomas Kerry McCarter and found 3 differences: Form D filed 58 days after the first sale; No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.